GSK/Clover's COVID-19 vaccine moves into human trials

Clover has initiated a Phase I study assessing the combination of its COVID-19 S-Trimer vaccine (SCB-2019) with GSK's pandemic adjuvant system, which can reduce the amount of protein required per vaccine dose. Preliminary safety and immunogenicity results are expected in August.

Source:

PharmaTimes